Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 9:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Progesterone Clear all
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Estradiol and Progesterone on Arginine Vasopressin Regulation and Serum Sodium Concentration

NCT00589134
View directory record Official record
Conditions
Exercise Induced Hyponatremia
Interventions
Gatorade Endurance Formula, ganirelix acetate
Dietary Supplement · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 4 Interventional Results available

Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality

NCT03720847
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone, Inactive Clear Patch, Placebo capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2019 · Synced Sep 11, 2026, 9:11 AM EDT
Terminated Phase 2 Interventional Results available

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

NCT01147016
View directory record Official record
Conditions
Breast Cancer
Interventions
HER2Bi-armed activated T cells, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, laboratory biomarker analysis, neoadjuvant therapy, therapeutic conventional surgery
Biological · Drug · Other + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Not applicable Interventional

Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer

NCT02186470
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma With Predominant Intraductal Component, Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Tubular Ductal Breast Carcinoma
Interventions
accelerated partial breast irradiation, intensity-modulated radiation therapy, image-guided radiation therapy, therapeutic conventional surgery
Radiation · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
50 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Results available

Oral Progesterone for Prevention of Preterm Birth

NCT01180296
View directory record Official record
Conditions
Preterm Birth
Interventions
oral micronized progesterone, Identical Placebo tablet
Drug
Lead sponsor
Fetal Medicine Foundation
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2019 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 2 Interventional

Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC

NCT00134680
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Letrozole, Trastuzumab
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Sep 11, 2026, 9:11 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Uterine Electrical Activity Before and After Progesterone Treatment for Preterm Labor

NCT01406197
View directory record Official record
Conditions
Preterm Labor
Interventions
Experimental: Vaginal progesterone, Experimental: Topical progesterone, Experimental: Intramuscular progesterone
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
17 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model

NCT04051320
View directory record Official record
Conditions
Perinatal Depression, Post Partum Depression, Depression, Postpartum, Depression
Interventions
Leuprolide Acetate 3.75 MG/ML, Estradiol 2 Mg tablet, Micronized progesterone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
22 Years to 45 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 2 Interventional Results available

Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery

NCT00559507
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
saracatinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vaginal Rings in Postmenopausal Women

NCT02092571
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Progesterone vaginal ring,
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 11, 2026, 9:11 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Progesterone in Gender Affirming Hormone Therapy Study

NCT06807580
View directory record Official record
Conditions
Transgender Women
Interventions
Placebo, Progesterone
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer

NCT00365599
View directory record Official record
Conditions
Breast Cancer
Interventions
suberoylanilide hydroxamic acid (SAHA, Vorinostat), tamoxifen citrate (Tamoxifen)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
8
States / cities
San Francisco, California • Boynton Beach, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 11, 2026, 9:11 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07248144, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
102
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Results available

Clinical Safety Study of the Progesterone Vaginal Ring in Women Undergoing Assisted Reproductive Technology Procedures

NCT03565211
View directory record Official record
Conditions
Progesterone Supplementation in Women Undergoing ART
Interventions
Progesterone vaginal ring
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 34 Years · Female only
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
15
States / cities
Tempe, Arizona • Encino, California • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

NCT00073528
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Lapatinib, Letrozole, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
84
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Jonesboro, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Sep 11, 2026, 9:11 AM EDT
Recruiting Phase 2 Interventional

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM

NCT06974604
View directory record Official record
Conditions
Breast Neoplasms, Lung Neoplasms
Interventions
Dexamethasone oral
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 2 Interventional Results available

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

NCT00057941
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
anastrozole, gefitinib, fulvestrant, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Progesterone & Postpartum Relapse to Smoking

NCT01798394
View directory record Official record
Conditions
Tobacco Use Cessation, Tobacco Use Disorder
Interventions
Progesterone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 11, 2026, 9:11 AM EDT
Active, not recruiting Phase 1 Interventional

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

NCT02208375
View directory record Official record
Conditions
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Endometrial Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, High Grade Ovarian Serous Adenocarcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Uterine Corpus Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Capivasertib, Laboratory Biomarker Analysis, Olaparib, Pharmacological Study, Vistusertib
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 3 Interventional Results available

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

NCT01547741
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Docetaxel, Paclitaxel
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
4,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
914
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 612 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 11, 2026, 9:11 AM EDT
Active, not recruiting Phase 2 Interventional

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

NCT02876107
View directory record Official record
Conditions
Breast Carcinoma, Breast Lump, Edema, Erythema, Estrogen Receptor Negative, HER2/Neu Negative, Inflammatory Breast Carcinoma, Invasive Breast Carcinoma, Peau d'Orange, Progesterone Receptor Negative, Triple-Negative Breast Carcinoma
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Panitumumab
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening

NCT01929083
View directory record Official record
Conditions
Prolonged QT Interval in EKG and Sudden Death
Interventions
Progesterone, Placebo, Ibutilide
Drug
Lead sponsor
Indiana University
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Sep 11, 2026, 9:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neural Changes in the Aging Auditory System

NCT00264407
View directory record Official record
Conditions
Progesterone, Estrogens, Hearing, Psychoacoustics, Auditory Perceptual Disorders
Interventions
Hormone Replacement Therapy - HRT
Drug
Lead sponsor
University of Rochester
Other
Eligibility
60 Years to 86 Years · Female only
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
2
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2005 · Synced Sep 11, 2026, 9:11 AM EDT
Completed Phase 1 Interventional

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

NCT00892736
View directory record Official record
Conditions
Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Breast Carcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Hereditary Breast and Ovarian Cancer Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Progesterone Receptor Negative, Prostate Carcinoma, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Solid Neoplasm, Triple-Negative Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Veliparib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
7
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Sep 11, 2026, 9:11 AM EDT